Summary

Persistence Market Research has recently released a comprehensive report on the global market for pulmonary fibrosis treatment. The report provides a detailed analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering valuable insights into the market landscape. This research publication offers exclusive data and statistics projecting the growth trajectory of the pulmonary fibrosis treatment market from 2024 to 2033.

Key Insights:

• Market Size (2024E): USD 3.1 Billion
• Projected Market Value (2033F): USD 5.6 Billion
• Global Market Growth Rate (CAGR 2024 to 2033): 6.8%

Pulmonary Fibrosis Treatment Market - Report Scope:

Pulmonary fibrosis treatment addresses a range of therapeutic approaches aimed at managing and potentially reversing the progression of fibrotic lung diseases. These treatments include pharmacological interventions, oxygen therapy, pulmonary rehabilitation, and in severe cases, lung transplantation. The market serves hospitals, specialty clinics, pulmonary rehabilitation centers, and homecare settings, offering a variety of treatment options such as antifibrotic drugs, immunosuppressants, and novel biologics.

Market Growth Drivers:

The global pulmonary fibrosis treatment market is driven by several factors, including increasing prevalence of respiratory disorders such as idiopathic pulmonary fibrosis (IPF) and sarcoidosis. Growing aging population and associated higher incidence of chronic diseases contribute significantly to market expansion. Advances in drug development, particularly the emergence of antifibrotic therapies like pirfenidone and nintedanib, bolster market growth by providing effective treatment options with improved patient outcomes. Additionally, rising awareness about early diagnosis and treatment initiation among healthcare providers and patients propels market demand.

Market Restraints:

Despite promising growth prospects, the pulmonary fibrosis treatment market faces challenges related to high treatment costs, limited availability of curative treatments, and stringent regulatory requirements for drug approval. Economic constraints in some regions, coupled with insufficient healthcare infrastructure, hinder market penetration, especially in developing countries. Furthermore, the complexity of diagnosing and managing pulmonary fibrosis necessitates specialized healthcare expertise, posing additional barriers to effective treatment.

Market Opportunities:
The pulmonary fibrosis treatment market presents opportunities driven by ongoing research and development initiatives focused on novel therapeutic targets and personalized medicine approaches. Technological innovations in diagnostic imaging and biomarker identification enhance disease detection and monitoring, facilitating early intervention and personalized treatment plans. Strategic collaborations between pharmaceutical companies and academic research institutions foster innovation and accelerate the introduction of breakthrough therapies. Moreover, the integration of telemedicine and digital health solutions expands patient access to specialized care and improves treatment adherence, thereby stimulating market growth.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the pulmonary fibrosis treatment market globally?
• Which treatment modalities and therapeutic classes are driving adoption across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the pulmonary fibrosis treatment market?
• Who are the key players contributing to the pulmonary fibrosis treatment market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global pulmonary fibrosis treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global pulmonary fibrosis treatment market, including major pharmaceutical companies and biotechnology firms, focus on expanding their product portfolios through strategic acquisitions, partnerships, and licensing agreements. Companies invest heavily in clinical trials to demonstrate efficacy and safety profiles of new treatments, ensuring regulatory approval and market acceptance. Furthermore, patient education initiatives and advocacy efforts by healthcare organizations raise awareness about pulmonary fibrosis, driving early diagnosis and treatment initiation.

Key Companies Profiled:

• F. Hoffman - La Roche Ltd.
• Boehringer Ingelheim
• International GmbH
• Cipla Ltd (Cipla)
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• FibroGen Inc.,
• Galecto, Inc.

Key Segments Covered in Pulmonary Fibrosis Treatment Industry Research

By Therapy Type:
• Monotherapy
• Combination Therapy
• Symptomatic Treatment

By Indication:
• Idiopathic Pulmonary Fibrosis (IPF)
• Familial PF
• Others

By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Mail Order Pharmacy

By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Key Success Factors
4.1. Pipeline Assessment
4.2. Disease Epidemiology
4.3. Key Promotional Strategies by Market Players
4.4. Adoption/ Indication Analysis by region
4.5. Regulatory Scenario
4.6. PESTEL Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Growth of Pharmaceutical Sector in Emerging nations
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. Growing Demand for Pulmonary Fibrosis Treatment
5.2.3. Pipeline assessments
5.2.4. Increasing Investment in Pharmaceutical
5.2.5. Costs of Pulmonary Fibrosis Treatment
5.2.6. Adoption of Pulmonary Fibrosis Treatment
5.2.7. Rise in Sales of Medical Devices
5.2.8. Regulatory Framework
5.2.9. Rising Disease Epidemic
5.2.10. Launch of New Drug
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Therapy Type
6.1.2. Revenue By Indication
6.1.3. Revenue By Distribution Channel
6.1.4. Revenue By Region
6.2. 2024 Market Scenario
7. Global Pulmonary Fibrosis Treatment Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033
7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Therapy Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Therapy Type, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Therapy Type, 2024-2033
8.3.1. Monotherapy
8.3.1.1. Pirfenidone Therapy
8.3.1.2. Nintedanib Therapy
8.3.1.3. Corticosteroids Therapy
8.3.2. Combination Therapy
8.3.2.1. Pirfenidone & Corticosteroid
8.3.2.2. Nintedanib & Corticosteroid
8.3.2.3. Pirfenidone & Antitussive
8.3.2.4. Others
8.3.3. Symptomatic Treatment
8.4. Market Attractiveness Analysis By Therapy Type
9. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Indication, 2024-2033
9.3.1. Idiopathic Pulmonary Fibrosis (IPF)
9.3.2. Familial PF
9.3.3. Others
9.4. Market Attractiveness Analysis By Indication
10. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Mail Order Pharmacy
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
12.1. Introduction
12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Therapy Type
12.3.3. By Indication
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Therapy Type
12.4.3. By Indication
12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. U.S. Pulmonary Fibrosis Treatment Market Analysis
12.8.1.1. .Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Therapy Type
12.8.1.2.2. By Indication
12.8.1.2.3. By Distribution Channel
12.8.2. Canada Pulmonary Fibrosis Treatment Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Therapy Type
12.8.2.2.2. By Indication
12.8.2.2.3. By Distribution Channel
13. Latin America Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
13.1. Introduction
13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
13.3.1. By Country
13.3.1.1. Mexico
13.3.1.2. Brazil
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Therapy Type
13.3.3. By Indication
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Therapy Type
13.4.3. By Indication
13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Mexico Pulmonary Fibrosis Treatment Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Therapy Type
13.8.1.2.2. By Indication
13.8.1.2.3. By Distribution Channel
13.8.2. Brazil Pulmonary Fibrosis Treatment Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Therapy Type
13.8.2.2.2. By Indication
13.8.2.2.3. By Distribution Channel
13.8.3. Argentina Pulmonary Fibrosis Treatment Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Therapy Type
13.8.3.2.2. By Indication
13.8.3.2.3. By Distribution Channel
14. Europe Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
14.1. Introduction
14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. U.K.
14.3.1.5. Spain
14.3.1.6. Russia
14.3.1.7. BENELUX
14.3.1.8. Rest of Europe
14.3.2. By Therapy Type
14.3.3. By Indication
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Therapy Type
14.4.3. By Indication
14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Germany Pulmonary Fibrosis Treatment Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Therapy Type
14.8.1.2.2. By Indication
14.8.1.2.3. By Distribution Channel
14.8.2. Italy Pulmonary Fibrosis Treatment Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Therapy Type
14.8.2.2.2. By Indication
14.8.2.2.3. By Distribution Channel
14.8.3. France Pulmonary Fibrosis Treatment Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Therapy Type
14.8.3.2.2. By Indication
14.8.3.2.3. By Distribution Channel
14.8.4. U.K. Pulmonary Fibrosis Treatment Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Therapy Type
14.8.4.2.2. By Indication
14.8.4.2.3. By Distribution Channel
14.8.5. Spain Pulmonary Fibrosis Treatment Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Therapy Type
14.8.5.2.2. By Indication
14.8.5.2.3. By Distribution Channel
14.8.6. Russia Pulmonary Fibrosis Treatment Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Therapy Type
14.8.6.2.2. By Indication
14.8.6.2.3. By Distribution Channel
14.8.7. BENELUX Pulmonary Fibrosis Treatment Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Therapy Type
14.8.7.2.2. By Indication
14.8.7.2.3. By Distribution Channel
15. East Asia Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Therapy Type
15.3.3. By Indication
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Therapy Type
15.4.3. By Indication
15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. China Pulmonary Fibrosis Treatment Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Therapy Type
15.8.1.2.2. By Indication
15.8.1.2.3. By Distribution Channel
15.8.2. Japan Pulmonary Fibrosis Treatment Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Therapy Type
15.8.2.2.2. By Indication
15.8.2.2.3. By Distribution Channel
15.8.3. South Korea Pulmonary Fibrosis Treatment Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Therapy Type
15.8.3.2.2. By Indication
15.8.3.2.3. By Distribution Channel
16. South Asia Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
16.1. Introduction
16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Therapy Type
16.3.3. By Indication
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Therapy Type
16.4.3. By Indication
16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Pulmonary Fibrosis Treatment Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Therapy Type
16.8.1.2.2. By Indication
16.8.1.2.3. By Distribution Channel
16.8.2. Indonesia Pulmonary Fibrosis Treatment Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Therapy Type
16.8.2.2.2. By Indication
16.8.2.2.3. By Distribution Channel
16.8.3. Malaysia Pulmonary Fibrosis Treatment Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Therapy Type
16.8.3.2.2. By Indication
16.8.3.2.3. By Distribution Channel
16.8.4. Thailand Pulmonary Fibrosis Treatment Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Therapy Type
16.8.4.2.2. By Indication
16.8.4.2.3. By Distribution Channel
17. Oceania Pulmonary Fibrosis Treatment Market 2019-2023 and Forecast 2024-2033
17.1. Introduction
17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Therapy Type
17.3.3. By Indication
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Therapy Type
17.4.3. By Indication
17.4.4. By Distribution Channel
17.5. Key Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Australia Pulmonary Fibrosis Treatment Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Therapy Type
17.8.1.2.2. By Indication
17.8.1.2.3. By Distribution Channel
17.8.2. New Zealand Pulmonary Fibrosis Treatment Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Therapy Type
17.8.2.2.2. By Indication
17.8.2.2.3. By Distribution Channel
18. Middle East and Africa (MEA) Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033
18.1. Introduction
18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
18.3.1. By Country
18.3.1.1. Turkey
18.3.1.2. GCC Countries
18.3.1.3. South Africa
18.3.1.4. North Africa
18.3.1.5. Rest of MEA
18.3.2. By Therapy Type
18.3.3. By Indication
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Therapy Type
18.4.3. By Indication
18.4.4. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Turkey Pulmonary Fibrosis Treatment Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Therapy Type
18.8.1.2.2. By Indication
18.8.1.2.3. By Distribution Channel
18.8.2. GCC Countries Pulmonary Fibrosis Treatment Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Therapy Type
18.8.2.2.2. By Indication
18.8.2.2.3. By Distribution Channel
18.8.3. South Africa Pulmonary Fibrosis Treatment Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Therapy Type
18.8.3.2.2. By Indication
18.8.3.2.3. By Distribution Channel
18.8.4. North Africa Pulmonary Fibrosis Treatment Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Therapy Type
18.8.4.2.2. By Indication
18.8.4.2.3. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Deep Dive
20.2.1. F. Hoffman - La Roche Ltd.
20.2.1.1. Overview
20.2.1.2. Service Portfolio
20.2.1.3. Key Financials
20.2.1.4. Sales Footprint
20.2.1.5. Strategy Overview
20.2.1.5.1. Marketing Strategy
20.2.1.5.2. Product Strategy
20.2.1.5.3. Channel Strategy
20.2.2. Boehringer Ingelheim
20.2.2.1. Overview
20.2.2.2. Service Portfolio
20.2.2.3. Key Financials
20.2.2.4. Sales Footprint
20.2.2.5. Strategy Overview
20.2.2.5.1. Marketing Strategy
20.2.2.5.2. Product Strategy
20.2.2.5.3. Channel Strategy
20.2.3. International GmbH
20.2.3.1. Overview
20.2.3.2. Service Portfolio
20.2.3.3. Key Financials
20.2.3.4. Sales Footprint
20.2.3.5. Strategy Overview
20.2.3.5.1. Marketing Strategy
20.2.3.5.2. Product Strategy
20.2.3.5.3. Channel Strategy
20.2.4. Cipla Ltd (Cipla)
20.2.4.1. Overview
20.2.4.2. Service Portfolio
20.2.4.3. Key Financials
20.2.4.4. Sales Footprint
20.2.4.5. Strategy Overview
20.2.4.5.1. Marketing Strategy
20.2.4.5.2. Product Strategy
20.2.4.5.3. Channel Strategy
20.2.5. Gilead Sciences, Inc.
20.2.5.1. Overview
20.2.5.2. Service Portfolio
20.2.5.3. Key Financials
20.2.5.4. Sales Footprint
20.2.5.5. Strategy Overview
20.2.5.5.1. Marketing Strategy
20.2.5.5.2. Product Strategy
20.2.5.5.3. Channel Strategy
20.2.6. Bristol-Myers Squibb Company
20.2.6.1. Overview
20.2.6.2. Service Portfolio
20.2.6.3. Key Financials
20.2.6.4. Sales Footprint
20.2.6.5. Strategy Overview
20.2.6.5.1. Marketing Strategy
20.2.6.5.2. Product Strategy
20.2.6.5.3. Channel Strategy
20.2.7. FibroGen Inc.,
20.2.7.1. Overview
20.2.7.2. Service Portfolio
20.2.7.3. Key Financials
20.2.7.4. Sales Footprint
20.2.7.5. Strategy Overview
20.2.7.5.1. Marketing Strategy
20.2.7.5.2. Product Strategy
20.2.7.5.3. Channel Strategy
20.2.8. Galecto, Inc.
20.2.8.1. Overview
20.2.8.2. Service Portfolio
20.2.8.3. Key Financials
20.2.8.4. Sales Footprint
20.2.8.5. Strategy Overview
20.2.8.5.1. Marketing Strategy
20.2.8.5.2. Product Strategy
20.2.8.5.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology